API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
Details:
Hyanutra™-RH Hair Nourishing Shield is a new hair moisturizing conditioner made from HA with different molecular weights and brown rice ferment filtrate by patented technology. It is especially suitable for damaged hair.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Hyanutra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Hyanutra™-RH Hair Nourishing Shield is a new hair moisturizing conditioner made from HA with different molecular weights and brown rice ferment filtrate by patented technology. It is especially suitable for damaged hair.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Hyanutra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
Skinvive™ by Juvéderm® is a smooth, injectable HA gel that contains a small amount of local anesthetic (lidocaine). It improves skin quality in the cheeks by smoothing the skin and increasing hydration.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Skinvive
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.
Lead Product(s): Hyaluronic Acid,Dermatan Sulfate,Collagen
Therapeutic Area: Dermatology Product Name: Dermial
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
Apsen’s Motilex HA combines two leading ingredients, b-2Cool native type II collagen and Mobilee, patented ingredient that synergistically combines a high concentration of hyaluronic acid with polysaccharides and collagen, to effectively maintain joint function.
Lead Product(s): Hyaluronic Acid,Type II Collagen
Therapeutic Area: Musculoskeletal Product Name: Motilex HA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apsen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 26, 2021
Details:
The study, conducted in a rabbit model of osteoarthritis, set out to evaluate the effects of b-2Cool native type II collagen in combination with CS b-Bioactive chondroitin sulphate, glucosamine hydrochloride and Mobilee® which is a rooster comb extract rich in hyaluronic acid.
Lead Product(s): Undenatured Type II Collagen,Chondroitin Sulfate,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: Mobilee
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2020
Details:
B-2Cool (Bioiberica’s native type II collagen) is an innovative ingredient, has been shown in four scientific studies to help maintain good joint health at a very low daily dose.
Lead Product(s): Undenatured Type II Collagen,Harpagophytum Procumbens Extract,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: Colnatur Forte
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
Juvederm Voluma™ XC (hyaluronic acid) is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Juvederm Volux XC
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Allergan Aesthetics looks to further develop the Hybrid Injectables category by introducing its first dual-effect product, which combines the two active ingredients - hyaluronic acid, a well-known ingredient found in facial fillers and calcium hydroxyapatite in one injection.
Lead Product(s): Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area: Dermatology Product Name: HArmonyCa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
JUVÉDERM® VOLBELLA® XC was first FDA–approved in 2016 for use in the lips and perioral rhytids.2 As the category leader, the JUVÉDERM® Collection of Fillers offers the broadest portfolio, and this latest approval marks the sixth approved indication in the U.S.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Dermatology Product Name: Juvéderm Volbella XC
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2022
Details:
JUVÉDERM (Hyaluronic Acid) is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in mid-face and for augmentation of chin region to improve chin profile in adults over age of 21.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Juvederm Volux XC
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
Princess Volume Plus (hyaluronic acid) dermal filler and Lidocaine with the intention to confirm the efficacy and safety in respect of mid-facial volume insufficiency and/or mid-facial profile deficient participants.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Dermatology Product Name: Princess Volume Plus
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Hyalofast is a highly differentiated, single-stage, bone preserving, hyaluronic acid matrix, which is intended to support the entrapment of mesenchymal stem cells obtained from autologous bone marrow aspirate concentrate for the repair of chondral and osteochondral lesions.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Hyalofast
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate osteoarthritis pain.
Lead Product(s): Clonidine,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: JTA-004
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Papilocare (hyaluronic acid) vaginal gel is the first treatment that has been scientifically proven to have a very high success rate in eliminating not only the human papiloma virus (HPV), but also precancerous lesions of the cervix.
Lead Product(s): Hyaluronic Acid,Coriolus Versicolor
Therapeutic Area: Infections and Infectious Diseases Product Name: Papilocare
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biovaxys
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 19, 2022
Details:
Pervistop (Epigallocatechin Gallate) once-daily supplement provides a true alternative to eradicating the root problem of HPV persistence, which can unpredictably evolve into cancer.
Lead Product(s): Green Tea Extract,Hyaluronic Acid,Vitamin B12
Therapeutic Area: Infections and Infectious Diseases Product Name: Pervistop
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH) and is used for the treatment of uncomplicated retinal detachment.
Lead Product(s): Hyaluronic Acid,Adipic Dihydrazide
Therapeutic Area: Ophthalmology Product Name: ABV-1701
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss and for augmentation of the chin region to improve the chin profile in adults over 21.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Juvederm Volux XC
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
The launch of saypha® VOLUME PLUS, a hyaluronic acid dermal filler, into the Canadian market will enhance the available line of saypha® dermal fillers, giving aesthetic medical professionals more creative power to design a truly bespoke experience for their patients.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Saypha
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
The prospective, single-arm study followed a population of 283 patients and determined that Solesta provided clinically significant, sustained improvement in symptoms and quality of life, without the occurrence of any serious adverse events.
Lead Product(s): Hyaluronic Acid,Dextranomer
Therapeutic Area: Gastroenterology Product Name: Solesta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
This investment supports development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therapies. HTL will produce methacrylate hyaluronic acid, a key component for specific parameters across the GelMEDIX pipeline.
Lead Product(s): Regenerative Medicine,Hyaluronic Acid
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: HTL Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 10, 2022
Details:
New oil-free moisturizer is formulated with HA Serum (hyaluronic acid), Vitamin C and unique botanical boosters to hydrate and repair the most challenged, dry, eczema-prone skin.
Lead Product(s): Hyaluronic Acid,Ascorbic Acid,Dragon Fruit
Therapeutic Area: Dermatology Product Name: Moisture Recovery HA Serum
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
Dermal Repair Complex helps combat the key causes of dermal breakdown — resulting in visibly firmer and more lifted skin, reduced wrinkles, enhanced radiance, and a significantly younger, healthier overall appearance.
Lead Product(s): Dimethyl Sulfone,Hyaluronic Acid,Collagen
Therapeutic Area: Dermatology Product Name: Dermal Repair Complex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
Phase 3 trial of its allogeneic cell therapy MPC-06-ID ( rexlemestrocel-L), showed a durable reduction in back pain lasting at least three years from a single intra-discal injection in patients with chronic low back pain (CLBP) associated with degenerative disc disease.
Lead Product(s): Rexlemestrocel-L,Hyaluronic Acid
Therapeutic Area: Neurology Product Name: MPC-06-ID
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2022
Details:
A key objective of MPC-06-ID (rexlemestrocel-L) is to demonstrate reduction in pain and opioid usage and and position rexlemestrocel-L as a potential opioid-sparing agent.
Lead Product(s): Rexlemestrocel-L,Hyaluronic Acid
Therapeutic Area: Neurology Product Name: MPC-06-ID
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Grunenthal
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
The non-dilutive capital provides financial support for commercial and product development including Barrigel, is made from NASHA. Barrigel is an injectable biodegradable material that separates prostate from rectum to protect it during radiation therapy for prostate cancer.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Oncology Product Name: Barrigel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Silicon Valley Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 28, 2021
Details:
EIB financing will support and prepare Bone Therapeutics’ lead asset, the enhanced viscosupplement JTA-004, being evaluated in a registrational phase III clinical trial for the treatment of osteoarthritic pain in the knee, for future regulatory approval and commercialization.
Lead Product(s): Plasma Proteins,Hyaluronic Acid,Fast-acting Analgesic
Therapeutic Area: Musculoskeletal Product Name: JTA-004
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 01, 2021
Details:
A single injection of rexlemestrocel-L may provide a durable, and effective opioid-sparing therapy for patients with chronic inflammatory back pain due to degenerative disc disease. Greatest benefits were seen when administered earlier in the disease process.
Lead Product(s): Rexlemestrocel-L,Hyaluronic Acid
Therapeutic Area: Neurology Product Name: MPC-06-ID
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
Details:
Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 2016 by the FDA for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds, in patients over age 21.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Dermatology Product Name: Restylane Defyne
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2021
Details:
JTA-004 is unique patented mix of plasma proteins, hyaluronic acid, and a fast-acting analgesic. Bone Therapeutics has completed recruitment and treated all patients in its pivotal Phase III clinical study with the improved viscosupplement in patients with knee osteoarthritis.
Lead Product(s): Plasma Proteins,Hyaluronic Acid,Fast-acting Analgesic
Therapeutic Area: Musculoskeletal Product Name: JTA-004
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
The JTA-004 Phase III study is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20, the leading current osteoarthritis treatment on the market.
Lead Product(s): Plasma Proteins,Hyaluronic Acid,Fast-acting Analgesic
Therapeutic Area: Musculoskeletal Product Name: JTA-004
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® collection of fillers.
Lead Product(s): Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area: Dermatology Product Name: HArmonyCa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovative Luminera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 07, 2020
Details:
The joint venture comprises Croma's Hyaluronic Acid Filler Princess® VOLUME and additional filler and facial aesthetic products and CNBG's multi-channel distribution, marketing experience and synergistic products, specifically its botulinum toxin product Heng Li®.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Hyaluronic Acid Filler Princess
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: China National Biotech Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 15, 2020
Details:
Company’s field force is established and will begin introducing its prestige aesthetics portfolio, including the RHA® Collection of dermal fillers, resilient hyaluronic acid, and the HintMD financial technology (fintech) platform, in the United States (U.S.) in September.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Dermatology Product Name: RHA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Funding will provide further financial support to Bone Therapeutics, in addition to recent financing, to advance its current pivotal phase III clinical study with the enriched protein solution, JTA-004.
Lead Product(s): Plasma Proteins,Hyaluronic Acid,Fast-acting Analgesic
Therapeutic Area: Musculoskeletal Product Name: JTA-004
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Funding August 13, 2020
Details:
FDA has granted Aquestive's AQST-108 Fast Track designation, an oral sublingual film formulation that delivers systemic epinephrine in development utilizing proprietary Aquestive PharmFilm ® technologies for treatment of allergic reactions, including anaphylaxis.
Lead Product(s): Hyaluronic Acid,Antibiotic
Therapeutic Area: Infections and Infectious Diseases Product Name: MoxiGel
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
Nestlé Health Science is incorporating Bioiberica’s patented ingredient, Mobilee®, into its MERITENE® Mobilis® joint-health drink mix.
Lead Product(s): Hyaluronic Acid,Type II Collagen,Polysaccharide
Therapeutic Area: Musculoskeletal Product Name: Meritene Mobilis
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bioiberica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 16, 2020
Details:
Under the terms of the agreement, Bayer Animal Health will distribute and market selected products from Bioiberica´s Companion Animal Health portfolio in eight countries.
Lead Product(s): Chondroitin Sulfate,Glucosamine,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: Condrovet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bioiberica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 09, 2020
Details:
The JTA-004 phase III study is a controlled, randomized, double-blind trial that will evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20.
Lead Product(s): Plasma proteins,Hyaluronic Acid,Fast-acting analgesic
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
Two studies are the pivotal JTA-004 Ph III clinical study targeting osteoarthritic knee pain and Ph IIb study of its allogeneic cell therapy product, ALLOB, in difficult tibial fractures.
Lead Product(s): Plasma proteins,Hyaluronic Acid,Fast-acting analgesic
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2020
Details:
The partnership with FILLMED will allow Crescita to expand its product offering in the medical aesthetic field with the addition of the hyaluronic acid ART-Filler® injectables range and NCTF® 135 HA.
Lead Product(s): Lidocaine,Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Crescita Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 20, 2020
Details:
Under the agreement Revance will gain immediate and exclusive rights to commercialize TEOXANE’s RHA® line of fillers in the U.S.
Lead Product(s): Hyaluronic Acid,Lidocaine
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Revance Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 09, 2020